Biotech Values

[DewDiligence]

FDA advisory panel votes 10-0 against Xarelto for secondary prevention of MACE (i.e. prevention following a recent MI):

http://in.reuters.com/article/2014/01/16/us-johsonjohnson-idINBREA0F1OY20140116

The panelists did not find the data from a single trial convincing, especially when considering that some data points were missing.

The panel’s decision has no effect on Xarelto’s approved FDA indications for AF/stroke prevention and VTE treatment/prevention.